Evaluating the effect of anti–cancer nano drugs dosage and reduced leukemia and polycythemia vera levels on trend of the human blood and bone marrow cancers under synchrotron radiation

Abstract

Leukemia is a cancer of the blood and bone marrow; there are many types of leukemia, depending on which type of white blood cell is involved. Treatment varies with the type and stage of disease. In fact, it is a blood cancer that begins in the marrow of our bones, the soft center where new blood cells grow. If we have polycythemia vera, our marrow makes too many red blood cells, which causes our blood to get too thick. That can make us more likely to have clots, a stroke, or a heart attack. Treatment of leukemia and polycythemia vera levels on trend of the human blood and bone marrow cancers for optimum usage of anti–cancer Nano drugs dosage is one of the most important issues of sustainable development. Therefore, the only available way to deal with the problem of treatment of leukemia and polycythemia vera levels on trend of the human blood and bone marrow cancers is optimum usage of anti-cancer Nano drugs dosage. In this study, we evaluated the chemical changes of anti–cancer Nano drugs dosage in human blood and bone marrow cancers’ cells such as leukemia, a type of cancer found in our blood and bone marrow cancers is caused by the rapid production of abnormal white blood cells. The high number of abnormal white blood cells is not able to fight infection, and they impair the ability of the bone marrow cancers to produce red blood cells and platelets and determine the treatment trend of these changes.